The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.

更灵敏的蛋白质生物标志物检测的发展导致可检测性的不断提高，将临床应用范围扩展到亚临床心血管疾病 (CVD) 的检测。然而，与现有风险评分相比，这些努力尚未导致风险评估的改进。非编码 RNA (ncRNA) 已被评估为生物标志物，而 miRNA 最受关注。最近，已经确定了其他 ncRNA 类别，包括长链非编码 RNA (lncRNA) 和环状 RNA (circRNA)。在这里，我们比较了心血管领域中新兴的 ncRNA 生物标志物与蛋白质生物标志物在临床应用中的潜力，重点关注心肌损伤。